Background Investigations for Persons or Entities With a Financial Interest in or Having a Management Responsibility for a Management Contract; Correction

CourtNational Indian Gaming Commission
Citation87 FR 2383
Record Number2022-00631
Publication Date14 January 2022
2383
Federal Register / Vol. 87, No. 10 / Friday, January 14, 2022 / Proposed Rules
There appear to be no legitimate
sources for 4-OH-DiPT, 5-MeO-AMT, 5-
MeO-MiPT, 5-MeO-DET, and DiPT as
marketed drugs and no accepted
medical use in the United States, but
DEA notes that these substances are
available for purchase from legitimate
suppliers for scientific research. There
is no evidence of significant diversion of
4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT,
5-MeO-DET, and DiPT from legitimate
suppliers.
DEA has identified 31 domestic
suppliers of one or more of the
following substances: 4-hydroxy-N,N-
diisopropyltryptamine (4-OH-DiPT), 5-
methoxy-alpha-methyltryptamine (5-
MeO-AMT), 5-methoxy-N-methyl-N-
isopropyltryptamine (5-MeO-MiPT), 5-
methoxy-N,N-diethyltryptamine (5-
MeO-DET), and N,N-
diisopropyltryptamine (DiPT). Thirty
(30) of the 31 domestic suppliers are not
registered with DEA to handle
controlled substances. The one
registered supplier is already registered
with DEA and has all security and other
handling processes in place, resulting in
minimal impact to this supplier.
Therefore, the remaining 30 non-
registered domestic suppliers are
affected. Since the vast majority of DEA
registrants are small entities or are
employed by small entities, all 30
affected suppliers are assumed to be
small entities. It is impossible to know
how much 4-hydroxy-N,N-
diisopropyltryptamine (4-OH-DiPT), 5-
methoxy-alpha-methyltryptamine (5-
MeO-AMT), 5-methoxy-N-methyl-N-
isopropyltryptamine (5-MeO-MiPT), 5-
methoxy-N,N-diethyltryptamine (5-
MeO-DET), and N,N-
diisopropyltryptamine (DiPT) are
distributed by these suppliers. It is
common for suppliers to have items on
their catalog while not actually having
any material level of sales. Based on the
discussion above, DEA believes any
quantity of sales from these distributors
for legitimate purposes is minimal.
Therefore, these suppliers are expected
to remove the product from their catalog
rather than incur the cost of obtaining
a DEA registration and physical security
for products with minimal sales.
Therefore, DEA estimates the cost of this
rule, in form of lost sales, if any, on the
affected small entities is minimal. DEA
welcomes any public comment
regarding this estimate.
Because of these facts, this proposed
rule will not, if promulgated, result in
a significant economic impact on a
substantial number of small entities.
Unfunded Mandates Reform Act of 1995
On the basis of information contained
in the ‘‘Regulatory Flexibility Act’’
section above, DEA has determined
pursuant to the Unfunded Mandates
Reform Act (UMRA) of 1995 (2 U.S.C.
1501 et seq.) that this proposed action
would not result in any Federal
mandate that may result ‘‘in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $100,000,000 or more
(adjusted annually for inflation) in any
1 year . . . .’’ Therefore, neither a Small
Government Agency Plan nor any other
action is required under UMRA of 1995.
List of Subjects in 21 CFR Part 1308
Administrative practice and
procedure, Drug traffic control,
Reporting and recordkeeping
requirements.
For the reasons set out above, DEA
proposes to amend 21 CFR part 1308 as
follows:
PART 1308—SCHEDULES OF
CONTROLLED SUBSTANCES
1. The authority citation for 21 CFR
part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b),
956(b), unless otherwise noted.
2. In § 1308.11, as proposed to be
amended at 86 FR 16553 (March 30,
2021), 86 FR 37719 (July 16, 2021), and
86 FR 69187 (December 7, 2021), add
paragraphs (d)(101) through (105) to
read as follows:
§ 1308.11 Schedule I.
* * * * *
(d) * * *
(101) 4-hydroxy-N,N-
diisopropyltryptamine (other names: 4-
OH-DiPT; 3-(2-
(diisopropylamino)ethyl)-1H-indol-4-ol)
7516.
(102) 5-methoxy-alpha-
methyltryptamine (Other names: 5-
MeO-AMT; 1-(5-methoxy-1H-indol-3-
yl)propan-2-amine) 7506.
(103) 5-methoxy-N-methyl-N-
isopropyltryptamine (Other names: 5-
MeO-MiPT; N-(2-(5-methoxy-1H-indol-
3-yl)ethyl)-N-methylpropan-2-amine)
7512.
(104) 5-methoxy-N,N-
diethyltryptamine (Other names: 5-
MeO-DET; N,N-diethyl-2-(5-methoxy-
1H-indol-3-yl)ethanamine) 7525.
(105) N,N-diisopropyltryptamine
(Other names: DiPT; N-(2-(1H-indol-3-
yl)ethyl)-N-isopropylpropan-2-amine)
7522.
* * * * *
Anne Milgram,
Administrator.
[FR Doc. 2022–00713 Filed 1–13–22; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF THE INTERIOR
National Indian Gaming Commission
25 CFR Part 537
RIN 3141–AA58
Background Investigations for Persons
or Entities With a Financial Interest in
or Having a Management
Responsibility for a Management
Contract; Correction
AGENCY
: National Indian Gaming
Commission, Department of the Interior.
ACTION
: Proposed rule; correction.
SUMMARY
: This document corrects the
preamble to a proposed rule published
in the Federal Register of December 2,
2021, regarding Background
Investigations for Persons or Entities
with a Financial Interest in or Having a
Management Responsibility for a
Management Contract. The document
contained incorrect dates for submitting
comments. This correction clarifies that
comments are due January 31, 2022.
FOR FURTHER INFORMATION CONTACT
:
Michael Hoenig, 202–632–7003.
SUPPLEMENTARY INFORMATION
:
Correction
In the Federal Register of December 2,
2021, in proposed rule FR Doc. 2021–
25844, on page 68446, in the second
column, change the
DATES
caption to
read:
DATES
: Written comments on this
proposed rule must be received on or
before January 31, 2022.
Dated: January 6, 2022.
Michael Hoenig,
General Counsel.
[FR Doc. 2022–00631 Filed 1–13–22; 8:45 am]
BILLING CODE 7565–01–P
DEPARTMENT OF THE INTERIOR
National Indian Gaming Commission
25 CFR Part 537
RIN 3141–AA77
Fees; Correction
AGENCY
: National Indian Gaming
Commission, Department of the Interior.
ACTION
: Proposed rule; correction.
SUMMARY
: This document corrects the
preamble to a proposed rule published
in the Federal Register of December 2,
2021, regarding Fees. The document
contained incorrect dates for submitting
comments. This correction clarifies that
comments are due January 31, 2022.
VerDate Sep<11>2014 16:36 Jan 13, 2022 Jkt 256001 PO 00000 Frm 00025 Fmt 4702 Sfmt 4702 E:\FR\FM\14JAP1.SGM 14JAP1
lotter on DSK11XQN23PROD with PROPOSALS1

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT